سعر جلوكوادجاست 5/500 مجم 30 قرص 2026

Glucoadjust 5/500 mg 30 f.c. tabs. — Empagliflozin + metformin (MUP (Medical Union Pharmaceuticals)).

• Synjardy (empagliflozin/metformin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (see full US label for CV risk reduction wording and limitations).Population: Adults with type 2 diabetesDailyMed (U.S. NLM)

• Severe renal impairment, end-stage renal disease, or dialysis; metabolic acidosis including diabetic ketoacidosis; hypersensitivity to empagliflozin, metformin or any excipient (see full label).International label, same formulation · DailyMed (U.S. NLM)

• Boxed/important warnings for metformin lactic acidosis; SGLT2-associated risks include ketoacidosis, volume depletion, urosepsis/pyelonephritis, genital mycotic infections, hypoglycemia with insulin/secretagogues, and lower-limb amputation risk signals historically discussed for class — follow current label.International label, same formulation · DailyMed (U.S. NLM)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing renal reabsorption of filtered glucose and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion (US label).
• Metformin: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; insulin secretion remains unchanged (US label).